Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics and Tolerability of Tacrolimus Tablet(TacroBell) in Kidney Transplant Recipients
NCT04102943Phase 4Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Nov 2017
- Primary completion
- Sep 2020
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of tacrolimus + Wuzhi capsule in kidney transplantation (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoints: Maximum concentration of drug in serum at 2 weeks and Area under the plasma concentration-time curve from time zero to time t at 2 weeks. Started Nov 2017; status: completed.
02
Drugs
tacrolimus + Wuzhi capsule
03
Conditions
kidney transplantation
Beyond the preview
Go deeper on NCT04102943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04102943.